These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 29651624)
21. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729 [TBL] [Abstract][Full Text] [Related]
22. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882 [TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Fadia M; Fookeerah P; Ali S; Shadbolt B; Greenaway T; Perampalam S Pathology; 2020 Apr; 52(3):318-322. PubMed ID: 32107082 [TBL] [Abstract][Full Text] [Related]
24. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation. Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496 [TBL] [Abstract][Full Text] [Related]
25. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy. Zwaenepoel K; Jacobs J; De Meulenaere A; Silence K; Smits E; Siozopoulou V; Hauben E; Rolfo C; Rottey S; Pauwels P Histopathology; 2017 Sep; 71(3):357-365. PubMed ID: 28383817 [TBL] [Abstract][Full Text] [Related]
26. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918 [TBL] [Abstract][Full Text] [Related]
27. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
28. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734 [TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive screening for PD-L1 expression in thyroid cancer. Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480 [TBL] [Abstract][Full Text] [Related]
32. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012 [TBL] [Abstract][Full Text] [Related]
33. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656 [TBL] [Abstract][Full Text] [Related]
34. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337 [TBL] [Abstract][Full Text] [Related]
35. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120 [TBL] [Abstract][Full Text] [Related]
37. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322 [TBL] [Abstract][Full Text] [Related]
38. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene. Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277 [TBL] [Abstract][Full Text] [Related]
40. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. Kim YH; Choi SE; Yoon SO; Hong SW Hum Pathol; 2014 Jul; 45(7):1483-8. PubMed ID: 24745617 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]